China's National Institutes for Food and Drug Control ingredient authority, NIDC, is seeking public comments on updated information covering 913 existing cosmetic ingredients — the latest maintenance step for the inventory that anchors every registration and notification filed under CSAR.

The consultation touches the IECIC, the Inventory of Existing Cosmetic Ingredients in China, which lists ingredients already in use on the Chinese market. For formulators and regulatory teams, the IECIC functions as the reference table for what counts as an "existing" ingredient versus what triggers the new-ingredient registration pathway with the NMPA. Any correction to an ingredient entry — INCI name, Chinese name, usage restrictions or supporting data — flows directly into dossiers, safety assessments and label reviews.

What does a consultation on 913 ingredients actually change?

NIDC periodically reviews and revises the entries of existing ingredients based on new technical data, usage history and feedback from industry. A batch of 913 entries under revision signals systematic housekeeping rather than a single-ingredient fix. Companies that manufacture, import or formulate with any of the affected ingredients should check whether the updated entries alter how their materials are named, restricted or documented.

For multinationals, the practical workload sits in dossier alignment. If an updated entry changes an ingredient's Chinese name or usage conditions, pending product notifications and registered product files may need consistent updates during their own cycles. For raw material suppliers, an updated entry can affect the technical documentation packages they provide to brand clients shipping to China.

Who should respond, and why now?

Public comment periods are the window in which suppliers and brands can submit evidence on their own ingredients — correcting names, clarifying historical use or arguing against disproportionate restrictions. Missing that window means living with the published entry until the next revision round.

Stakeholders with technical data on ingredients in the batch — concentration of use, safety history, function claims — have a direct interest in reviewing the updated entries before they are finalized. Comment procedures typically run through the designated NIDC submission channel, and the agency consolidates feedback before issuing the revised inventory information.

How does this fit China's broader ingredient framework?

The consultation is part of the steady post-CSAR machinery: the NMPA approves new ingredients individually, while NIDC maintains and refines the stock of existing ones. Recent years have seen the regulator tighten expectations on safety data even for legacy ingredients, and inventory updates are one instrument for encoding that stricter standard.

For procurement teams, an updated IECIC entry can influence supplier qualification. If an entry adds restrictions or clarifies sourcing requirements, brands may need to re-verify certificates of analysis and impurity profiles against the revised text before next shipments.

What comes next?

After the comment period closes, NIDC will review submissions and publish the finalized updated information for the 913 ingredients. The next data points to watch are the closing date of this consultation, the publication of the consolidated revisions, and any follow-up guidance from the NMPA on how updated entries apply to products already on the market.

Companies formulating for China should assign someone to screen the 913-entry list against their portfolios this week; the correction window, not the publication date, is when their data can still shape the outcome.